Skip to main content
INOVIO PHARMACEUTICALS, INC. logo

INOVIO PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · INO ISIN · US45773H4092 LEI · 529900B9W875XDZXTM97 US Manufacturing
Filings indexed 1,003 across all filing types
Latest filing 2025-05-16 Director's Dealing
Country US United States of America
Listing US INO

About INOVIO PHARMACEUTICALS, INC.

https://www.inovio.com/

INOVIO PHARMACEUTICALS, INC. is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines. The company's core technology centers on designing proprietary DNA plasmids—small, circular DNA molecules that instruct the body's cells to produce specific, targeted proteins to combat disease. These DNA medicines are delivered into cells using the company's proprietary investigational CELLECTRA® smart devices. This platform is designed to enable in vivo protein production and achieve therapeutic effect without the use of chemical adjuvants, lipid nanoparticles, or viral vectors. The company's development pipeline targets HPV-related diseases, various cancers, and infectious diseases.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2025-05-16 English
FORM 4
Director's Dealing
2025-05-16 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-05-14 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 13, 2025, by Inovio Pharmaceuticals, Inc. It announces the issuance of a press release with financial results for the quarter ended March 31, 2025. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes the press release as an exhibit. This matches the characteristics of an Earnings Release (ER), which is the initial announcement of quarterly financial results. The document is under 5,000 characters and serves as a current report announcing earnings results, not a full quarterly or annual report. Therefore, the correct classification is Earnings Release (ER).
2025-05-13 English
10-Q
Interim / Quarterly Report Q1 2025
2025-05-13 English
FORM 4
Director's Dealing
2025-05-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.